All In Biotech

Drug Trial Radar · NCT06775834

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function

Safety and Pharmacokinetic Study of HRS-1893 Tablets in Subjects With Mild and Moderate Renal Insufficiency and Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Feb 11, 2025

Primary completion

Jul 23, 2025

Study completion Jul 23, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate pharmacokinetics of HRS-1893 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.

Conditions

  • Hypertrophic Cardiomyopathy

Interventions

  • HRS-1893Drug

    HRS-1893 tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration (Cmax)Time frame: 0 hour to 16 days after the dosing.
  2. Area under the plasma concentration-time curve from time zero to the time of last quantifiable analyte concentration (AUC0-t)Time frame: 0 hour to 16 days after the dosing.
  3. Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞)Time frame: 0 hour to 16 days after the dosing.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.